|
Association of the PHB_1630_C > T polymorphism with ovarian cancer risk in BRCA1 carriers |
||||
| All cases and controls |
||||
|
|
||||
| Genotype |
Cases (n = 127) n (%) |
Controls (n = 127) n (%) |
ORcrudeb (95% CI) |
p |
|
|
||||
| PHB_1630_C > T |
||||
| CC |
101 (80) |
102 (80) |
1.00 (reference) |
|
| CT+TTa |
26 (20) |
25 (20) |
1.05 (0.54–2.04) |
1.00 |
|
|
||||
| Cases and controls with risk factor information |
||||
|
|
||||
| Genotype |
Cases (n = 83) n (%) |
Controls (n = 83) n (%) |
ORadjc (95% CI) |
p |
|
|
||||
| PHB_1630_C > T |
||||
| CC |
64 (77) |
65 (78) |
1.00(reference) |
|
| CT+TTa |
19 (23) |
18 (18) |
1.34 (0.59–3.11) |
0.49 |
|
a Due to the low proportion of <3% in patients and controls, CT and TT genotypes were combined. b ORcrude: crude odds ratio. c ORadj: odds ratio adjusted for age at menarche, age of first live birth, parity, breastfeeding, OC use, HRT, smoking and BMI. | ||||
Jakubowska et al. BMC Cancer 2008 8:90 doi:10.1186/1471-2407-8-90 |
||||